Get the Stockscreener App
0.90
0.00%
0.00
After Hours:
.90
Eagle Pharmaceuticals Inc stock is traded at $0.90, with a volume of 31,196.
It is up +0.00% in the last 24 hours and down -76.15% over the past month.
See More
Previous Close:
$0.90
Open:
$0.6912
24h Volume:
31,196
Relative Volume:
33.01
Market Cap:
$N/A
Revenue:
$257.55M
Net Income/Loss:
$11.95M
P/E Ratio:
0.989
EPS:
0.91
Net Cash Flow:
$-9.39M
1W Performance:
-50.00%
1M Performance:
-76.15%
6M Performance:
-81.21%
1Y Performance:
-93.26%
1-Day Range:
$0.6501
$0.90
1-Week Range:
$0.6501
$0.90
52-Week Range:
$0.6501
$0.90
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Compare EGRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| EGRX | 0.90 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-01-18 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Mar-21-18 | Reiterated | Mizuho | Underperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | RBC Capital Mkts | Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-09-17 | Downgrade | Mizuho | Neutral → Underperform |
| Nov-16-16 | Downgrade | Mizuho | Buy → Neutral |
| Nov-03-16 | Upgrade | Mizuho | Neutral → Buy |
| Nov-03-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-26-16 | Reiterated | Mizuho | Buy |
| Aug-16-16 | Reiterated | Mizuho | Neutral |
| Jun-20-16 | Downgrade | Mizuho | Buy → Neutral |
| May-10-16 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-18-16 | Reiterated | Mizuho | Buy |
| Feb-26-16 | Reiterated | Mizuho | Buy |
| Dec-09-15 | Initiated | Mizuho | Buy |
| Jul-29-15 | Reiterated | Piper Jaffray | Overweight |
View All
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
Eagle Pharmaceuticals to Delist from Nasdaq By Investing.com - Investing.com Australia
Eagle Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
Eagle Pharmaceuticals to Delist from Nasdaq - Investing.com India
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration - The Manila Times
Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension | EGRX Stock News - StockTitan
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Citigroup Inc's Strategic Reduction in Eagle Pharmaceuticals Inc Shares - GuruFocus.com
Creative Planning Makes New $59,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerWOODCLIFF LAKE, N.J. — November 12, 2024 — Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) recently announced the appointment of Christopher Krawtschuk as the Chief - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - The Manila Times
Eagle Pharmaceuticals Taps Former Bluebird Bio CFO Krawtschuk to Lead Finance | EGRX Stock News - StockTitan
Nantahala Capital Management Reduces Stake in Eagle Pharmaceuticals - GuruFocus.com
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’S Disease in Collaboration with University of Pennsylvania - Marketscreener.com
Eagle Pharmaceuticals Adopts Stockholder Rights Plan to Protect Shareholders’ Interests - Defense World
Union Square Park Capital Management, LLC Increases Stake in Eagle Pharmaceuticals Inc - GuruFocus.com
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan - The Manila Times
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle - GlobeNewswire
Pemetrexed Market Is Booming Worldwide 2024-2031 | Stada - openPR
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceutica - GuruFocus.com
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - ForexTV.com
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire Inc.
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire
Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares - Yahoo Finance
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Point72 Asia Singapore Pte. Ltd. Makes New $65,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
AVEO Up After-Hours, Plandaí Gets Facelift, SNTA Enchants, Keep Watch On Eagle - RTTNews
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Selling Buzz: Eagle Pharmaceuticals Inc [EGRX] CEO Tarriff Scott sells 10,925 shares of the company - Knox Daily
Eagle Pharmaceuticals, Inc.(OTCPK: EGRX) dropped from NASDAQ Composite Index - Marketscreener.com
Post-Trade Analysis: Eagle Pharmaceuticals Inc (EGRX) Slides -39.89, Closing at 2.14 - The Dwinnex
EGRX stock touches 52-week low at $2.78 amid market challenges By Investing.com - Investing.com South Africa
EGRX stock touches 52-week low at $2.78 amid market challenges - Investing.com
The Future of Eagle Pharmaceuticals Inc: Analyzing EGRX - The InvestChronicle
Eagle Pharmaceuticals : Non Reliance of Financial Report Form 8 K - Marketscreener.com
Rhumbline Advisers Decreases Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Global Antiemetics And Antinauseants Market Innovations Investigated by Analysis and Share 2024 - WhaTech
173,365 Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Bought by Perceptive Advisors LLC - Defense World
Towa Pharmaceutical Settles Patent Infringement Suit - TipRanks
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Bendamustine Market 2024 Growth Potential, Manufacturers, Production, Revenue and Forecast 2032 Teva, Eisai, Eagle Pharmaceuticals, MundiPharma – Cauverynews - Cauverynews
Emergent Sinks on New Orders for Smallpox, Mpox Vaccine - Baystreet.ca
Emergent Biosolutions Shares Rise 16% on Orders Secured for Smallpox, Monkeypox Vaccines - MarketWatch
Fidelis Capital Partners LLC Purchases New Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Acadian Asset Management LLC Sells 26,056 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
First Eagle Investment Management LLC Grows Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Beta Blockers Global Market Report 2024: Size, Growth Rate, and Segments - WhaTech
From Rs 5.97 to Rs 47.25 per share in just 137 days: Debt-free multibagger penny stock hit back-to-back upper circuits & 52-week highs; Here’s why! - Dalal Street Investment Journal
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
LSV Asset Management Reduces Stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.15%
Cap:
|
Volume (24h):